Post on 10-Aug-2020
2017CancerProgramReport
BayMedicalSacredHeartHealthSystem|2017CancerProgramReport 1
CancerProgramReport2017
B AY M E D I C A L C E N T E R S A C R E D H E A R T H E A LT H S Y S T E M
TheBayMedicalCancerProgramisaComprehensiveCommunityCancerProgramthathas
been accreditedby theAmericanCollegeof SurgeonsCommissiononCancer since 1997.
The program is guided by the leadership of a multidisciplinary Cancer Committee. This
CommitteeprovidesdirectionandreviewofcancercareandservicesatBayMedical.
Cancer education, prevention and screening are fundamental functions of the program,
withacommitmenttoimprovethehealthandwell-beingofpatients,communitymembers
and staff. In collaboration with numerous healthcare professionals on staff as well as
community partners, a variety of events and activities were offered in 2017. These
opportunitiesweredevelopedwith a focus onCommitteeprioritized topics andhigh risk
groups. Throughout the year, lung cancer screeningwas available through theuseof the
Low-DoseCTthoraxscreeningwiththe128-sliceCTScanner.Thebroadarrayofactivities
providingeducation forpreventionandscreening in2017 includedtheannualHealthFair
withamedicaloncologistasaneducationalspeaker;aColonCancerSeminar;SkinCancer
Screenings; Relay for Life; Look Good, Feel Better classes; a Mammogram Awareness
Campaign;MakingStridesAgainstBreastCancersponsorship;aWomen’sHealthFairwith
520 registered attendees; participation in the Great American Smoke-out; and the
distributionofeducationalcommunicationsviamultiplemediavenues.
RelayforLife
BayMedicalSacredHeartHealthSystem|2017CancerProgramReport 2
CancerRegistry
TheBayMedicalSacredHeartCancerRegistryprovidesdatamanagementservicesforstate
andnational cancer case incidence and cancer survival data; analyzes statistics for quality
purposes;meetsdatarequestsofclinicians,administrators;andmaintainscompliancewith
statereportingregulations.
TheCancerRegistryatBayMedicalwasestablishedwithareferencedateofJanuary1,1999.
In 2017, the Registry received the 2016 Jean Byers Award for Excellence in Cancer
RegistrationfromtheFloridaCancerDataSystem(FCDS).
TheRegistryisresponsibleforcollecting,managing,andanalyzingcancerdata.Incompliance
with the standards of the American College of Surgeons, Commission on Cancer, lifetime
follow-up ismaintainedonallanalyticcases (casesnewlydiagnosedand/or treatedatBay
Medical).Follow-upprovidesasourcefortrackingoutcomesandsurvivalstatistics.
StatisticalreportsfromtheRegistryareutilizedtostudytreatmentoutcomes,evaluatethe
qualityofpatientcare,assistinformulatingcancerpreventionandscreeningprogramsand
administrativeplanning,andevaluatecommunityhealthinitiatives.
CancercasesaresubmittedtotheFloridaCancerDataSystemasrequiredbystatelaw.All
analytic casesare reportedannually to theNationalCancerDataBase (NCDB)andeligible
casesarereportedmonthlytotheRapidQualityReportingSystem(RQRS),asrequiredofan
approvedcancerprogrambytheAmericanCollegeofSurgeonsCommissiononCancer.
CancerRegistryData
Summaryof2016StatisticsIn 2016, the Registry added 679 new cases into the database.Of these, 516 cancer cases
seenatBayMedicalSacredHeartwereanalytic.Theanalytictopprimarycancersiteswere
lung, breast, colorectal, non-Hodgkin lymphoma, melanoma, bladder, and thyroid. These
sites account for 69% of the newly diagnosed and/or treated cancers seen in 2016. The
remaining cases were new to Bay Medical and treated with active disease (non-analytic
cases).
BayMedicalSacredHeartHealthSystem|2017CancerProgramReport 3
Astatisticalreviewofthemajorsitesofcanceralongwithareviewofthecalendaryear is
includedasfollows:
26.2%
14.7%
12.6%
5.0%
3.5%
3.5% 3.5%
MajorSites2016AnalyticCases
Lung
Breast
Colorectal
Non-HodgkinLymphoma
Melanoma,Skin
Bladder
Thyroid
Male- 246
, 47.7%
Female-270,52.3%
GenderDistribution2016AnalyticCases
BayMedicalSacredHeartHealthSystem|2017CancerProgramReport 4
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Lung Colorectal Breast NHL Melanoma
Bladder Thyroid
Male 50% 64% 1% 80% 67% 72% 28.0% Female 50% 36% 99% 20% 33% 28% 72.0%
TopFivePrimarySitesbyGender2016AnalyticCases
0%
5%
10%
15%
20%
25%
30%
Lung Breast Colorectal NHL Melanoma BladderBMSH 26% 15% 13% 5% 4% 4% FL 14% 14% 8% 4% 5% 5% USA 13% 15% 8% 4% 5% 5%
BayMedicalMostFrequentCancerIncidenceComparedtoState&NationalIncidenceEstimates,2016
BayMedicalSacredHeartHealthSystem|2017CancerProgramReport 5
SiteDistributionofNewlyDiagnosedAnalyticCases,2016
TOTAL MALE FEMALE
OralCavity&Pharynx 6 6 0 DigestiveSystem 107 70 37 RespiratorySystem 139 70 69 Bone&Joints 1 1 0 SoftTissue 4 2 2 Skin,ExcludingBasal&Squamous 18 12 6 Breast 76 1 75 FemaleGenitalSystem 28 0 28 MaleGenitalSystem 7 7 0 UrinarySystem 34 26 8 Brain&OtherNervousSystem 25 12 13 EndocrineSystem 20 5 15 Lymphoma 28 16 12 Leukemia 4 3 1 Mesothelioma 2 2 0 Unknown/Other
17
13
4
BayMedicalSacredHeartHealthSystem|2017CancerProgramReport 6
ColonCancerStudyEvidence points to improved rates of curative secondary treatment after detection of a
recurrence in patients who participate in a surveillance program after initial curative
resection of colon cancer. The success of surveillance for early detection of curable
recurrencedependsonpatientandprovideradherencetorecommendedschedules.1
In order to evaluate follow-up colon cancer surveillance schedules, a 2017 study on
colonoscopies for colon cancer cases diagnosed and treated at BayMedical in 2016 was
conductedtoevaluatethecarepatientsreceived.
TheNationalComprehensiveCancerNetwork(NCCN)Guidelinesspecifythatcolonoscopies
should be performed one year after resection or at 3 to 6 months post resection if not
performedpreoperativelybecauseofanobstructing lesion. TheQualityOncologyPractice
Initiative (QOPI) and the American Society of Clinical Oncology (ASCO) specify that
colonoscopies should be performed before or within 6 months of curative colorectal
resectionorcompletionofprimaryadjuvantchemotherapy.
Allcoloncancercasesdiagnosedin2016werereviewed.Findingsconcludedthatalleligible
patientsreceivedtheappropriatetreatmentaccordingtotheabovesurveillanceguidelines.1Practice Guidelines for the Surveillance of Patients After Curative Treatment of Colon and Rectal Cancer;TheAmericanSocietyofColon&RectalSurgeons.2015.
AccountabilityandQualityImprovementMeasures
BayMedicalSacredHeartparecipates in theRapidQualityReporengSystem(RQRS)of the
AmericanCollegeofSurgeons.RQRSisareporengandqualitytoolusedtoproviderealeme
assessment of the program’s adherence to quality cancer measures for various types of
cancer. This allows physicians to track clinical performance on naeonal quality indicators.
Parecipaenginthisacevityonamonthlybasisprovidesamethodtoevaluatecareinaemely
manneranddevelopappropriatequalityimprovements.
BayMedicalSacredHeartHealthSystem|2017CancerProgramReport 7
Another way care is evaluated by the Cancer Commifee is through parecipaeon in the
CancerProgramPraceceReports (CP3R)naeonalbenchmarkingprogramfromtheNaeonal
Cancer Database and supported by the American College of Surgeons. The performance
ratesofcarereceivedbypaeentswithbreast,colon,gastric,lung,andrectalcancerwhohave
documentaeon of treatment are compared to naeonal standard of care guidelines and
evidence-basedpracece.ThegoalsforthestandardsaresetforthbytheAmericanCollegeof
SurgeonsCommissiononCancer(CoC).
BayMedicalSacredHeartPerformance:Allstandardswithapplicablecaseswerecompliant
forthemostrecentyearevaluatedbeingeitheratorexceedingtheestablishedstandardgoal
/performanceratepercentagebelowasspecifiedbytheCoC.
Breast
Standard:Radiaeon isadministeredwithin1year(365days)ofdiagnosis forwomenunder
age70receivingbreastconservaeonsurgeryforbreastcancer.CoCStandard:90%
Standard: Tamoxifen or third generaeon aromatase inhibitor is recommended or
administeredwithin1year(365days)ofdiagnosis forwomenwithAJCCT1corStage IB-III
hormonereceptorposievebreastcancer. CoCStandard:90%
Standard: Radiaeon therapy is recommended or administered following any mastectomy
within1year(365days)ofdiagnosisofbreastcancerforwomenwith>=4posieveregional
lymphnodes. CoCStandard:90%
Standard: Image or palpaeon-guided needle biopsy to the primary site is performed to
establishdiagnosisofbreastcancer. CoCStandard:80%
Colon
Standard: At least 12 regional lymph nodes are removed and pathologically examined for
resectedcoloncancer. CoCStandard:85%
BayMedicalSacredHeartHealthSystem|2017CancerProgramReport 8
Gastric
Standard: At least 15 regional lymph nodes are removed and pathologically examined for
resectedgastriccancer. CoCStandard:80%
Lung
Standard:Systemicchemotherapyisadministeredwithin4monthstodaypre-operaevelyor
day of surgery to 6 months postoperaevely, or it is recommended for surgically resected
caseswithpathologiclymphnode-posieve(pN1)and(pN2)NSCLC.CoCStandard:85%
Standard:SurgeryisnotthefirstcourseoftreatmentforcN2,M0lungcases.
CoCStandard:85%
Rectum
Standard:PreoperaevechemoandradiaeonareadministeredforclinicalAJCCT3N0,T4N0,
or Stage III; or postoperaeve chemo and radiaeon are administered within 180 days of
diagnosisforclinicalAJCCT1-2N0withpathologicAJCCT3N0,T4N0,orStageIII;ortreatment
isrecommended;forpaeentsundertheageof80receivingreseceonforrectalcancer.
CoCStandard:85%
BayMedicalSacredHeartHealthSystem|2017CancerProgramReport 9
615NorthBonitaAvenuePanamaCity,FL32401